These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31940970)

  • 1. Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.
    Liguori L; Monticelli M; Allocca M; Hay Mele B; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests.
    Andreotti G; Citro V; De Crescenzo A; Orlando P; Cammisa M; Correra A; Cubellis MV
    Orphanet J Rare Dis; 2011 Oct; 6():66. PubMed ID: 22004918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.
    Andreotti G; Guarracino MR; Cammisa M; Correra A; Cubellis MV
    Orphanet J Rare Dis; 2010 Dec; 5():36. PubMed ID: 21138548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
    Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
    J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.
    Monticelli M; Liguori L; Allocca M; Bosso A; Andreotti G; Lukas J; Monti MC; Morretta E; Cubellis MV; Hay Mele B
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical studies.
    Germain DP; Fan JQ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S111-7. PubMed ID: 20040321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.
    Yam GH; Bosshard N; Zuber C; Steinmann B; Roth J
    Am J Physiol Cell Physiol; 2006 Apr; 290(4):C1076-82. PubMed ID: 16531566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones.
    Cammisa M; Correra A; Andreotti G; Cubellis MV
    Orphanet J Rare Dis; 2013 Jul; 8():111. PubMed ID: 23883437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
    Citro V; Peña-García J; den-Haan H; Pérez-Sánchez H; Del Prete R; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    PLoS One; 2016; 11(10):e0165463. PubMed ID: 27788225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A thermodynamic assay to test pharmacological chaperones for Fabry disease.
    Andreotti G; Citro V; Correra A; Cubellis MV
    Biochim Biophys Acta; 2014 Mar; 1840(3):1214-24. PubMed ID: 24361605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.
    Fan JQ; Ishii S
    Methods Enzymol; 2003; 363():412-20. PubMed ID: 14579593
    [No Abstract]   [Full Text] [Related]  

  • 12. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.
    Citro V; Cammisa M; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ).
    Thirumal Kumar D; Judith E; Priyadharshini Christy J; Siva R; Tayubi IA; Chakraborty C; George Priya Doss C; Zayed H
    Adv Protein Chem Struct Biol; 2019; 114():341-407. PubMed ID: 30635085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.
    Monticelli M; Hay Mele B; Allocca M; Liguori L; Lukas J; Monti MC; Morretta E; Cubellis MV; Andreotti G
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.
    Fan JQ; Ishii S
    FEBS J; 2007 Oct; 274(19):4962-71. PubMed ID: 17894781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
    Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
    Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.